SogoTrade Research Center








For Company Research, enter symbol or keyword and choose type of research:    Symbol Search
Johnson & Johnson
(NYSE: JNJ) Add to Portfolio
$130.60
-0.67 (-0.51%)
as of 14:28 EST

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine(TM) oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including prostate, colorecta (full story)
JNJ: 130.60 (-0.67), TROV: 1.60 (-0.02)
The National Pharmaceutical Council (NPC) today announced that Blasine Penkowski, MBA, Chief Strategic Customer Officer of Johnson & Johnson Health Care Systems Inc., has been elected Chair of NPC's Board of Directors for 2019-202 (full story)
JNJ: 130.60 (-0.67)
ProteKt Therapeutics, a biotech company developing new PKR kinase inhibitor-based therapies for neurodegenerative diseases including Alzheimer's Disease, today announced the signing of a binding agreement for a $US 3.6 million equ (full story)
JNJ: 130.60 (-0.67)
Eisbach Bio GmbH was announced as the winner of the BIO-Europe® 2019 Startup Slam competition, held in Hamburg. Andreas Ladurner, Chief Scientific Officer of Eisbach Bio, receives a complimentary registration to BIO-Europe Spr (full story)
JNJ: 130.60 (-0.67)
The "Analgesics Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering. (full story)
JNJ: 130.60 (-0.67)
The "Vision Care Devices And Equipment Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering. (full story)
JNJ: 130.60 (-0.67)
Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has announced its decision to voluntarily withdraw the European and other health authority filings still under review to extend the in (full story)
JNJ: 130.60 (-0.67)
BANGKOK (AP) — Shares were mixed in Asia on Tuesday as investors awaited cues on trade talks between China and the U.S. (full story)
JNJ: 130.60 (-0.67), MRO: 11.92 (+0.05), BA: 367.90 (+5.40)
--These are the first Phase 3 results evaluating p19-specific interleukin (IL)-23 inhibition in active psoriatic arthritis (full story)
JNJ: 130.60 (-0.67)
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced 24-week Phase 3 data showing a significantly greater proportion of patients with active psoriatic arthritis (PsA) treated with TREMFYA® (guselkumab) ach (full story)
JNJ: 130.60 (-0.67)
 
© 2019 Market data provided and hosted by Barchart Market Data Solutions. Fundamental company data provided by Morningstar and Zacks Investment Research. SEC Filings provided by Edgar Online. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.